Przejdź do treści
Global sound
AI Access Brief Podcast

AI Access Brief Podcast

autor: Carl Haakon

Najnowszy odcinek
PROTACs, VBID, RWE Frameworks

O tym podcaście

AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.

Odcinki

Najnowsze 20 z 178 odcinków

  • PROTACs, VBID, RWE Frameworks · 5 min · Sezon 1 Odcinek 173Episode 173 — 20 November 2026 New FDA approval for PROTACs, CMS VBID model expansion, NICE RWE framework for digital therapeutics, and EMA PRO reflection paper. Hosted by…
  • PBM Insulin Settlement & Gene Therapy Value · 7 min · Sezon 1 Odcinek 172Episode 172 — 19 November 2026 Analysis of FTC insulin settlement, subcutaneous Leqembi access, CMS value-based purchasing, and NICE RWE framework shifts. Hosted by Marcus and…
  • RWE Accelerated Approvals & IRA Evidence Shifts · 7 min · Sezon 1 Odcinek 171Episode 171 — 18 November 2026 Examining the evolving role of real-world evidence in accelerated approvals, IRA's influence on evidence strategies, and persistent value…
  • FDA RWE Guidance & PBM Pricing Shifts · 10 min · Sezon 1 Odcinek 170Episode 170 — 17 November 2026 Analyzing FDA's new RWE guidance for accelerated approvals, CMS's 2027 Star Ratings methodology, FTC-CVS insulin settlement impact, and NICE's…
  • US Market Access Trends · 6 min · Sezon 1 Odcinek 169Episode 169 — 16 November 2026 Examining recent US healthcare access challenges, Alzheimer's treatment innovations, insulin pricing settlements, and evolving HEOR strategies…
  • Gene Therapy Value Frameworks · 9 min · Sezon 1 Odcinek 168Episode 168 — 15 November 2026 Examining evolving value frameworks for gene therapies, focusing on evidence requirements, threshold adjustments, and payment model innovations…
  • HCA Access Crisis & Leqembi Implications · 7 min · Sezon 1 Odcinek 167Episode 167 — 14 November 2026 Examining HCA's profit warning as a signal of access erosion, subcutaneous Leqembi's implications, FTC's insulin settlement impact, and ICER's…
  • HCA Warning, Leqembi SubQ, Insulin Settlement, ICER Advice · 9 min · Sezon 1 Odcinek 166Episode 166 — 12 November 2026 HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value narrative; FTC-CVS insulin settlement exposes PBM…
  • Access Erosion & Evidence Shifts · 10 min · Sezon 1 Odcinek 165Episode 165 — 11 November 2026 Examining systemic access pressures from hospital operators, new Alzheimer's evidence demands, PBM pricing transparency, and proactive HEOR…
  • FDA RWE Guidance & PBM Pricing Shifts · 10 min · Sezon 1 Odcinek 164Episode 164 — 10 November 2026 FDA updates RWE standards for post-marketing studies, FTC cracks down on PBM insulin pricing, ICER expands early-phase advice, and HCA's profit…
  • HCA Warning, Leqembi SubQ, FTC CVS, ICER Advice · 9 min · Sezon 1 Odcinek 163Episode 163 — 08 November 2026 HCA's profit warning signals US access erosion; subcutaneous Leqembi reshapes Alzheimer's value narrative; FTC-CVS insulin settlement exposes PBM…
  • RWE, PBMs, and Value Advice · 9 min · Sezon 1 Odcinek 162Episode 162 — 07 November 2026 This week, we cover the FDA's draft guidance on real-world evidence, the FTC's settlement with CVS Caremark, ICER's expansion of early-phase…
  • VBID Models, Surrogate Endpoints, DCT Guidance · 8 min · Sezon 1 Odcinek 161Episode 161 — 06 November 2026 CMS launches VBID model for chronic conditions, NICE revises surrogate endpoint frameworks, and FDA releases DCT guidance for oncology drugs…
  • HTA Methodology Shifts & RWE Integration · 9 min · Sezon 1 Odcinek 160Episode 160 — 05 November 2026 Examining evolving HTA methodologies, RWE integration challenges, and operational hurdles in US/EU access frameworks. Hosted by Marcus and Sara…
  • FDA RWE Guidance & PBM Insulin Settlement · 10 min · Sezon 1 Odcinek 159Episode 159 — 04 November 2026 Examining new FDA guidance on RWE for post-marketing studies, FTC's landmark insulin pricing settlement with CVS, CMS Star Rating changes, and…
  • ESG in Pricing & RWE Evolution · 7 min · Sezon 1 Odcinek 158Episode 158 — 03 November 2026 Examining how ESG metrics reshape drug pricing, RWE's expanding role in HTA, and the impact of AI on evidence generation. Hosted by Marcus and…
  • HCA Warning, Leqembi, FTC, ICER · 6 min · Sezon 1 Odcinek 157Episode 157 — 02 November 2026 HCA signals access erosion in US healthcare; new subcutaneous Leqembi approved; FTC settles with CVS Caremark over insulin pricing; ICER expands…
  • FDA RWE Guidance & Value Framework Updates · 10 min · Sezon 1 Odcinek 156Episode 156 — 01 November 2026 This episode examines FDA's new RWE guidance, CMS Star Rating changes, NICE's digital therapeutics framework, and the first wave of EU oncology…
  • FDA RWE Guidance & CMS Value Models · 9 min · Sezon 1 Odcinek 155Episode 155 — 31 October 2026 Examining FDA's RWE guidance for post-marketing studies, CMS's new hospital value model, ISPOR's digital therapeutics framework, and EMA's AI…
  • Access Brief 154: HCA, Leqembi, FTC & ICER · 9 min · Sezon 1 Odcinek 154Episode 154 — 30 October 2026 Examining HCA's profit warning as an access erosion signal, subcutaneous Leqembi's HEOR implications, FTC-CVS insulin settlement impact on PBMs…

Na żywo, ostatnia godzina: 6 110 utworów na 2 141 stacjach w 106 krajach

Odkrywaj świat przez radio

Więcej sposobów na odkrywanie (7)

Usłyszałeś coś fajnego? Zapisz to albo otwórz od razu w Spotify.

★ Artysta tygodnia Najszybciej rosnący w radiu w tym tygodniu
Twój utwór tutaj? Od € 9 tygodniowo →
Radio 538 luisteren - Live!Teraz popularne